QA: Inozyme Pharma Inc. in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001693011_2023_Inozyme_Pharma_Inc.pdf

Logs

warning Missing logo subcommand.report {}

Graph

Absolute values for 0001693011, Inozyme Pharma Inc.

  xvar xval
0 AssetsCurrent 131,393,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 2,018,000
3 remainder_Assets 5,784,000
4 LiabilitiesCurrent 14,715,000
5 LiabilitiesNoncurrent 1,947,000
6 remainder_Liabilities 4,139,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 20,826,000
9 ResearchAndDevelopmentExpense 47,849,000
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome 1,614,000
13 remainder_ComprehensiveNetIncome -223,000
  yvar yval
0 Assets 139,195,000
1 Liabilities 20,801,000
2 Expenses 68,675,000
3 Revenues 0
4 StockholdersEquity 118,394,000
5 NetIncome -67,061,000
6 ComprehensiveNetIncome -67,172,500
7 BaseVar 115,254,000
8 EconomicCapitalRatio 1.71

Edgar->Model Mapping

Feature Distribution

Change over Time